Should I invest in HDFC Pharma and Healthcare Fund?

We don't give personal investment advice. HDFC Pharma and Healthcare Fund - Growth Option is suitable for an investor whose:time horizon is **5+ years** — equity funds can drop 30-50% in bad years; horizons under 5 years materially raise the risk of selling at a lossrisk tolerance accepts seeing the portfolio fall sharply without panic-sellinggoal isn't capital preservation in the short termCross-check the numbers above against alternatives before deciding.

HDFC

HDFC Pharma and Healthcare Fund - Growth Option

Latest NAV

₹20.8080

As of

17 Jul 2026

685 NAV records on file

NAV history & peer comparison

All NAVs split-adjusted and normalised to 100 at the start of the selected period, so funds with very different absolute NAV scales can be compared on one axis.

Period

Add another fund to compare

No matches.

Compares up to 8 funds. Click any line in the legend above to hide/show it.

Returns matrix

Fund return alongside the category average and peer rank for every standard window. Returns under one year are absolute; one year and longer are compound annualised (CAGR).

Window	Fund	Category avg	+/− vs avg	Rank	Quartile
1D	-0.87%	-0.07%	-0.80	102 / 122	Q4
1W	+0.71%	-0.15%	+0.86	16 / 122	Q1
2W	+0.43%	-0.13%	+0.57	31 / 122	Q2
1M	+6.40%	+1.33%	+5.07	4 / 122	Q1
3M	+16.82%	+3.32%	+13.50	1 / 122	Q1
6M	+22.10%	+2.87%	+19.23	2 / 122	Q1
YTD	+21.12%	+1.43%	+19.69	4 / 122	Q1
1Y	+17.93%	+2.53%	+15.40	8 / 120	Q1
2Y	+22.70%	+1.69%	+21.02	4 / 116	Q1
3Y	—	—	—	—	—
4Y	—	—	—	—	—
5Y	—	—	—	—	—
7Y	—	—	—	—	—
10Y	—	—	—	—	—
Inception	+30.24%	+11.17%	+19.08	2 / 122	Q1

Quartile legend: Q1 top 25% Q2 25-50% Q3 50-75% Q4 bottom 25%

Calendar-year returns

Full-year performance vs category average. Current year is partial (year-to-date).

Year	Fund	Category avg	+/− vs avg	Rank
2026 YTD	+21.12%	+1.37%	+19.74	4 / 118
2025	+0.84%	+3.20%	-2.36	56 / 115
2024	+49.92%	+19.60%	+30.31	1 / 113
2023	—	—	—	—

Rolling returns

Removes start-date bias by averaging CAGR over every overlapping N-year window in the fund's history. Higher average plus tight min/max plus high "% positive" = consistent.

1-Year rolling

+22.92%

22 windows

min 3.4% · max 62.6%

100% positive

Limited basis — fund is young, so this average may be skewed by which 1Y windows happen to be available.

3-Year rolling

—

Insufficient history

5-Year rolling

—

Insufficient history

7-Year rolling

—

Insufficient history

SIP returns — historical "what if"

If you had invested every month in this fund over the chosen period, this is what your investment would be worth today.

Period

Total invested

₹ —

Today's value

₹ —

XIRR

Annualised

Wealth multiplier

Period	Total invested	Today's value	XIRR	Wealth multiplier

XIRR is the annualised internal rate of return on the SIP cash flow — invariant to the monthly amount. "Today's value" and "Total invested" scale linearly with the slider. Past performance does not guarantee future returns. Excludes exit load and taxes.

Peers in Sectoral/Thematic Fund

Scheme	Fund house	NAV	As of
HDFC Banking & Financial Services Fund - Growth Option	HDFC	₹18.4020	17 Jul 2026
Nippon India Japan Equity Fund- Growth Plan- Bonus Option	Nippon India	₹27.0439	17 Jul 2026
Magnum Equity Fund -Dividend	SBI	₹75.2678	17 Jul 2026
ICICI Prudential Active Momentum Fund - Growth	ICICI Prudential	₹10.7400	17 Jul 2026
Franklin Asian Equity Fund - Dividend Plan	Franklin Templeton	₹20.5340	17 Jul 2026
Franklin India Multi-Factor Fund- Growth	Franklin India	₹9.5442	17 Jul 2026
Kotak Infrastructure & Economic Reform Fund - Standard Plan-Growth	Kotak	₹68.7640	17 Jul 2026
Canara Robeco Infrastructure-DIVIDEND	Canara Robeco	₹64.5500	17 Jul 2026
UTI - MNC Fund (UGS 10000)-Growth Option	UTI	₹397.9086	17 Jul 2026
BANK OF INDIA Manufacturing & Infrastructure Fund-Growth	Bank of India	₹66.3400	17 Jul 2026

Recent NAVs

Date	NAV
17 Jul 2026	₹20.8080
16 Jul 2026	₹20.9910
15 Jul 2026	₹20.9630
14 Jul 2026	₹20.7900
13 Jul 2026	₹20.6660
10 Jul 2026	₹20.6610
9 Jul 2026	₹20.6210
8 Jul 2026	₹20.3140
7 Jul 2026	₹20.5340
6 Jul 2026	₹20.6970

Frequently asked questions

These answers are generated from this fund's live metrics — NAV, returns, peer rank, drawdown, SIP backtest. Numbers refresh nightly after AMFI's NAV feed lands.

As of 17 Jul 2026, the NAV of HDFC Pharma and Healthcare Fund - Growth Option is ₹20.8080. It's a Sectoral/Thematic Fund from HDFC, run as a Unknown plan Growth option. NAVs update once per business day from the AMFI feed.

HDFC Pharma and Healthcare Fund - Growth Option has NAV history starting from 04 Oct 2023, a track record of about 2 years 9 months. It's a relatively new scheme. With under 5 years of NAVs, peer comparison is the best yardstick — point-to-point returns can be skewed by entry timing.

HDFC Pharma and Healthcare Fund - Growth Option is managed by HDFC. It's classified by AMFI under the 'Sectoral/Thematic Fund' SEBI category, which determines its peer set and tax treatment.

Over the trailing 1-year window, HDFC Pharma and Healthcare Fund - Growth Option has delivered a absolute return of 17.93% — +15.4 pp ahead of the Sectoral/Thematic Fund category average of 2.53%. The fund ranks #8 of 120 in its category — the top (Q1) quartile.

HDFC Pharma and Healthcare Fund - Growth Option doesn't have a complete 3-year window yet (we need at least 3 year of NAVs). Check the shorter-window returns above.

HDFC Pharma and Healthcare Fund - Growth Option doesn't have a complete 5-year window yet (we need at least 5 year of NAVs). Check the shorter-window returns above.

HDFC Pharma and Healthcare Fund - Growth Option doesn't yet have a 3-year CAGR on file, so a ₹1 lakh growth projection isn't reliable.

A ₹10,000 monthly SIP in HDFC Pharma and Healthcare Fund - Growth Option over the last 1 year — total invested ₹120,000 — would be worth ₹141,248 today. That's an XIRR (money-weighted annualised return) of 34.36%.

HDFC Pharma and Healthcare Fund - Growth Option doesn't yet have 10 years of NAVs. Over the longest available window (1-year SIP), ₹10,000/month would have grown to ₹141,248 — XIRR 34.36%.

HDFC Pharma and Healthcare Fund - Growth Option doesn't yet have a peer rank on file — typically because its category set is too small or it lacks the required NAV history. Compare manually using the returns table above.

HDFC Pharma and Healthcare Fund - Growth Option doesn't have a computed drawdown figure yet.

Consistency stats for HDFC Pharma and Healthcare Fund - Growth Option need at least 3 years of NAVs to compute. They'll populate automatically once the fund has enough history.

In calendar year 2025, HDFC Pharma and Healthcare Fund - Growth Option returned 0.84% — lagging the Sectoral/Thematic Fund category average of 3.20% by 2.36 pp. It ranked #56 of 115 in its category that year.

HDFC Pharma and Healthcare Fund - Growth Option is classified as an Equity fund (at least 65% equity exposure). Tax rules (post Budget 2024): if you hold 12 months or more, gains are Long-Term and taxed at 12.5% on the amount exceeding ₹1.25 lakh per financial year. Held for under 12 months, gains are Short-Term and taxed at 20%. The ₹1.25 L exemption is per PAN per FY across all equity LTCG.

We don't give personal investment advice. HDFC Pharma and Healthcare Fund - Growth Option is suitable for an investor whose:

time horizon is **5+ years** — equity funds can drop 30-50% in bad years; horizons under 5 years materially raise the risk of selling at a loss
risk tolerance accepts seeing the portfolio fall sharply without panic-selling
goal isn't capital preservation in the short term

Cross-check the numbers above against alternatives before deciding.

Educational content only — not investment advice. Tax rules summarised above reflect Budget 2024; consult a qualified adviser before transacting.

HDFC Pharma and Healthcare Fund - Growth Option

NAV history & peer comparison

Returns matrix

Calendar-year returns

Rolling returns

SIP returns — historical "what if"

Peers in Sectoral/Thematic Fund

Recent NAVs

Frequently asked questions

More from HDFC